Loading...
Loading...
Browse all stories on DeepNewz
VisitValar Labs Secures $22M Series A for AI-Powered Cancer Tool Vesta
May 30, 2024, 04:07 PM
Valar Labs has launched an AI-powered cancer care prediction tool, Vesta, aimed at predicting treatment responses in bladder cancer. The biotech startup secured $22 million in a Series A funding round led by DCVC and a16z. The tool can scan digital histology slices from tumors to predict disease progression and treatment outcomes, potentially saving time for patients. Valar Labs plans to expand the application of this tool to other types of cancer. The company has rolled out its first test and notes that there are roughly 2 million new cancer diagnoses annually in the US alone.
View original story
Markets
No • 50%
Yes • 50%
Official financial statements or press releases from Valar Labs
Yes • 50%
No • 50%
Press release or official announcement from a major US cancer treatment center
No • 50%
Yes • 50%
FDA announcement or Valar Labs press release
Prostate Cancer • 25%
Colorectal Cancer • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Official announcements or press releases from Valar Labs
University • 25%
Pharmaceutical Company • 25%
Other Healthcare Provider • 25%
Cancer Research Institution • 25%
Official announcements or press releases from Valar Labs
MD Anderson Cancer Center • 25%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Johns Hopkins Hospital • 25%
Official announcements or press releases from healthcare organizations